SCHEMBL2120931

SCHEMBL2120931

O=[N+]([O-])C1=CC([N+](=O)[O-])=CC([N+](=O)[O-])[CH]1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20160786 0.64
SCHEMBL4365635 0.58 MEN1 (0.33)
SCHEMBL3679428 0.58
SCHEMBL378762 0.55
SCHEMBL16178868 0.52
SCHEMBL651428 0.47 MEN1 (0.75)
SCHEMBL1332061 0.47
SCHEMBL9314153 0.47 MEN1 (0.75)
SCHEMBL30620980 0.47 MEN1 (0.75)
SCHEMBL8378095 0.47 MEN1 (0.75)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110719916-B Anti-TRKB antibodies 勃林格殷格翰国际有限公司 2024-05-31 CN disclosed
WO-2024099816-A1 METHOD, LIPOSOME COLLECTION, AND KIT FOR DETERMINING COMPLEMENT ACTIVITY UNIVERSITÄT REGENSBURG (DE) 2024-05-16 WO disclosed
US-20240101689-A1 ANTI-TRKB ANTIBODIES BOEHRINGER INGELHEIM INT (DE) 2024-03-28 US disclosed
US-11866501-B2 Anti-TrkB antibodies BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-01-09 US disclosed
US-11059879-B2 Chimeric antigen receptor molecules and uses thereof BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2021-07-13 US disclosed
US-20200399378-A1 ANTI-TRKB ANTIBODIES BOEHRINGER INGELHEIM INT (DE) 2020-12-24 US disclosed
US-10793634-B2 Anti-TrkB antibodies BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2020-10-06 US disclosed
EP-3635004-A1 ANTI-TRKB ANTIBODIES Boehringer Ingelheim International GmbH (DE) 2020-04-15 EP disclosed
US-10610504-B2 Alpha-cell re-generation combined with conversion to beta cells INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2020-04-07 US disclosed
EP-3368075-B1 CHIMERIC ANTIGEN RECEPTOR MOLECULES AND USES THEREOF UNIV TEXAS (US) 2020-01-29 EP disclosed
US-20030165875-A1 Novel receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof BIOXELL S.P.A. (IT) 2003-09-04 US disclosed
EP-0638119-B1 CHIMERIC RECEPTOR GENES AND CELLS TRANSFORMED THEREWITH YEDA RES & DEV (IL) 2003-06-11 EP disclosed
US-20020137697-A1 CHIMERIC RECEPTOR GENES AND CELLS TRANSFORMED THEREWITH CABARET BIOTECH LTD. (IL) 2002-09-26 US disclosed
WO-2001092291-A2 ANTIBODY AND T-CELL RECEPTOR LIBRARIES GALIM - GALIL IMMUNOLOGY LTD. (IL) 2001-12-06 WO disclosed
EP-0969867-A2 USE OF ANTI-IL-12 ANTIBODIES IN TRANSPLANTATION REJECTION Strom, Terry (US) 2000-01-12 EP disclosed
WO-1999022766-A2 USE OF ANTI-IL-12 ANTIBODIES IN TRANSPLANTATION REJECTION STROM TERRY (US) 1999-05-14 WO disclosed
EP-0638119-A4 CHIMERIC RECEPTOR GENES AND CELLS TRANSFORMED THEREWITH. YEDA RES & DEV (IL) 1997-06-18 EP disclosed
WO-1997015669-A1 CHIMERIC RECEPTOR GENES AND CELLS TRANSFORMED THEREWITH THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1997-05-01 WO disclosed
EP-0638119-A1 CHIMERIC RECEPTOR GENES AND CELLS TRANSFORMED THEREWITH YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 1995-02-15 EP disclosed
WO-1993019163-A1 CHIMERIC RECEPTOR GENES AND CELLS TRANSFORMED THEREWITH YEDA RESEARCH AND DEVELOPMENT CO, LTD. (IL) 1993-09-30 WO disclosed